PIK3CA and neoplasm: However, extensive proteomic analysis of clinical samples from patients enrolled in clinical trials of PI3K inhibitors is challenged by the ability to obtain sufficient tumor materials and the difficulty of obtaining serial samples, limiting biomarker development and the understanding of resistance mechanisms in individual patients.